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Abstract

General self-efficacy (GSE), the expectation that one is able to perform a behavior successfully, may differentiate
those who are able to successfully utilize self-care symptom management strategies (SCSMS). This subanalysis
(n = 569) of an international 12 site longitudinal randomized controlled trial (RCT) (n = 775), investigated GSE as
an important factor determining symptom burden, SCSMS, engagement with the provider, and medication
adherence over time, and identified differences in those with high and low GSE ratings concerning these
variables. Parametric and nonparametric repeated-measures tests were employed to assess GSE and the perceived effectiveness of SCSMS for anxiety, depression, diarrhea, fatigue, nausea, and neuropathy. Symptom
burden, engagement with the provider, and antiretroviral adherence were analyzed with regard to GSE. Our
data indicated that there were differences in the perceived symptom burden over time of HIV infected individuals by GSE. Those individuals with higher GSE had fewer symptoms and these symptoms were perceived to
be less intense than those experienced by the low GSE group. There were few meaningful differences in the
SCSMS used by those with high versus low GSE other than the use of illicit substances in the low GSE group.
The low GSE group was also significantly ( p = < 0.001) less engaged with their healthcare providers. Given the
difference in substance use by perceived GSE, and the importance of engagement with the healthcare provider,
more attention to the resolution of the concerns of those with low GSE by healthcare providers is warranted.
Introduction

G

eneral self-efficacy (GSE), the expectation that ‘‘one
can successfully perform a behavior,’’ has been of interest to investigators for decades.1 Bandura noted that ‘‘the
freedom to exert some control over one’s life’’ is an aspect of
agent causality (p. 7). He stated that ‘‘perceived self-efficacy is
not a measure of the skills one has but a belief about what one

can do under different sets of conditions with whatever skills
one possesses’’ (p. 37).2 Sherer and Adams observed that selfefficacy is influenced by past experience, suggesting that the
level of GSE reflects success or lack thereof in dealing with
previous life challenges, and is attained in the process of socialization from child to adult.3 The individual carries this
reservoir of experience forward to the challenges posed by
new situations.4
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Bandura and others noted the importance of assessing selfefficacy for discrete areas as a performance component is
involved. Although instruments have been developed to
measure such performance areas as coping self-efficacy,5,6
HIV treatment adherence self-efficacy,7 and HIV-self-efficacy,8
there are other performance areas where instruments are not
available. In those instances, and to obtain a more global
perspective, a GSE instrument may be a suitable approach to
examine the relationships of interest, in this case GSE and the
perceived effectiveness of self-care symptom management
strategies (SCSMS) and symptom burden. In this study, we
explored the relationship between GSE and the SCSMS selected by people living with HIV infection.
Management of symptoms and side effects
Both the symptoms related to HIV/AIDS and the side effects of antiretroviral (ARV) therapy, whether physical or
psychological, affect not only quality of life but the willingness and ability of HIV-infected individuals to maintain the
level of adherence required for suppression of HIV.9 Whereas
some infected individuals will contact their healthcare provider
(HCP) about various symptoms, others will seek to remediate
the conditions through a process of self-care management
using the advice of family members, friends, and other HIVinfected individuals. Those individuals who have reported
their symptoms to their provider may also engage in self-care
management, particularly if the symptoms persist.
A series of studies have investigated the self-care strategies
engaged in by HIV-infected individuals for anxiety, depression, diarrhea, fatigue, nausea, and neuropathy.10–12 These
strategies subsequently were organized into a self-care symptom management manual and compared with a manual containing information on nutrition based on the World Health
Organization HIV/AIDS Nutrition Guide.13 Although the
self-care symptom management manual was found to have a
higher helpfulness rating than the nutrition manual, there is a
paucity of information regarding whether attributes of the
individual affect self-care symptom management, including
whether ARV adherence and the relationship with the HCP
differs for those with higher general self-efficacy.
Relationship with the HCP has been shown to be associated
with better treatment adherence.14,15 Bakken and colleagues
found that the characteristic of the patient/client associated
with less engagement with the care provider was past or
present injection drug use.16 Age, ethnicity, and gender,
however, were not found to have statistically significant relationships with engagement with the provider. Bakken and
colleagues did not examine the psychological attributes of the
patient in this study. Such characteristics may be key to understanding the relationship with the provider as well as with
self-care symptom management, symptom burden, and ARV
adherence.
The importance of an ‘‘informed, activated patient’’ and a
‘’’prepared, proactive practice team’’ are emphasized by
Seaton in his discussion of the chronic care model.17 He observes that HIV/AIDS is considered a chronic disease but is
nonetheless distinct. The factors that make HIV/AIDS unique
include the complexity of ARV adherence, the lack of immediate feedback as to health status as is available for diabetes,
the discrimination accompanying an HIV diagnosis, and the
stigma of disease related to perceived culpability for disease
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acquisition and its’ communicability. To produce an informed, activated patient, Seaton advocated self-management
education, which he contrasted with traditional health and
illness education. Where self-management education emphasized problem solving skills, health education has as its
focus ‘‘disease specific information and technical skills’’ (p. 4).
The assumption that provision of health education in and
of itself is sufficient to produce the desired effect assumes that
the rational person will engage in the necessary behavior
based on the education provided. Such an assumption fails to
ascertain what the patient has heard in the communication
and what obstacles might impede achieving the necessary
behavior. Traditional health education also neglects to identify similar behaviors with which the patient was successful in
achieving the desired outcome. Furthermore, such an approach does not assess the patient’s general self-efficacy in
achieving desired outcomes.
Research with other disease populations as well as those
with HIV/AIDS has demonstrated that higher self-efficacy
affects health status,18 levels of depression and active coping,19 patient health behaviors,20 self-management by kidney
transplant recipients,21 HIV disease progression,22 and medication adherence.23
We explored the relationship of GSE with the use of SCSMS,
symptom burden, ARV adherence, and engagement with the
provider by a subanalysis of a data set developed as an international, longitudinal randomized controlled trial (RCT) that
examined the usefulness of a self-care symptom manual.13
The conceptual model depicted in Fig. 1 portrays the relationships of interest to this study, which are specified by the
research question, ‘‘Is perceived general self-efficacy related to
self-care management strategies, perceived symptom burden,
antiretroviral medication adherence, and engagement with
the provider over time for persons living with HIV infection?’’
Methods
Design
A descriptive, repeated measures design was used for this
secondary analysis of data from an existing study.13
Sample
This study utilized data from the experimental arm of an
RCT in which persons living with HIV infection received the
HIV/AIDS Self Care Symptom Management Manual. There

Environmental/contextual
Factors
Demographic factors
• Personal
Gender; Age;
Ethnicity
• Achieved
Education;
Work
• Medical Status
HIV- years;
Taking ARVsyears;
Knows viral load

Conceptual Model
Regulatory factors/modifiers

General self-efficacy

Outcomes

Self-care Symptom
Management
Strategies
Symptom Burden
Medication Adherence
Engagement with Provider

FIG. 1. Conceptual model depicting relationships of environmental/contextual factors, regulatory factors, and outcomes.

EXPLORING CONTRIBUTION OF SELF-EFFICACY
were a total of 775 participants in the experimental arm of the
parent study and 569 completed the general self-efficacy scale,
and therefore became the sample for this analysis.
Protection of human subjects
The coordinating site for this study was the University of
California–San Francisco, whose investigators obtained
overall approval for this research as well as San Francisco site
approval. In order to participate in the study, each site obtained approval from their Protection of Human Subjects
Committee. As this was a clinical trial, a Data Safety and
Monitoring Board was established at the University of California–San Francisco to monitor the performance and safety
of the trial. Certificates of confidentiality were also obtained as
required by each site’s Human Subjects Review Committee.
This clinical trial was registered with the National Institutes of
Health (NIH) at (ClinicalTrials.gov).
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rate frequently experienced HIV symptoms on a Likert scale
where 1 = mild, 2 = moderate, and 3 = severe.28 Part 1 consists
of 45 items clustering into 11 factors with a total score and
reliability estimates ranging from 0.76 to 0.91. Part 2 consists
of 19 HIV-related symptoms that do not cluster into factor
scores but may be of clinical interest. Part 3 is composed of 8
gynecological items. Cronbach’s a reliability scores ranged
from 0.85 to 0.90 for each of the factors and 0.92 for the items in
Parts 1 and 2.28
7. HIV/AIDS Targeted Quality of Life Instrument (HATQoL) is a 34 item HIV-specific quality of life measurement
assessing nine dimensions including overall function, life
satisfaction, health worries, financial worries, medication
worries, HIV mastery, disclosure, provider trust, and sexual
function.29–31 All dimensions are scored so that the final dimension score is transformed to a linear 0–100 scale where 0 is
the worst possible score and 100, the best possible score.

Instruments
Seven instruments were used for this analysis.
1. Demographic Questionnaire A 13 item self-report demographic questionnaire was used to collect demographic
and illness background information. This questionnaire has
been used in prior research by members of the International
HIV/AIDS Nursing Research Network.
2. GSE Scale is a 10 item scale designed to assess optimistic
self-beliefs about coping with a variety of life’s demands.24 Originally developed in German, the GSE Scale is available in 29
languages and has been widely used with participants from
numerous countries. Responses range from 1 (not at all true) to 4
(exactly true). Cronbach’s a ranged from 0.76 to 0.90.
3. Engagement with HCP is a 13 item scale designed to
assess how individuals rate their interactions with their
HCP.16 A four point scale (1 = always true and 4 = never true)
measured each item. A low score indicated greater provider
engagement. Cronbach’s a reliability estimate was 0.96.
4. HIV Self-Care Symptom Management Survey (HIVSCSMS) is composed of two parts.25 The first part assesses the
frequency, intensity, and impact of depression, anxiety, nausea, neuropathy, diarrhea, and fatigue. The second part of the
instrument examines the use of self-care behaviors, querying
whether the behavior is used (yes/no), frequency of use
(daily, weekly, monthly) and effectiveness of the strategy
(1 = not at all effective to 10 = very effective).
5. Revised AIDS Clinical Trials Group (ACTG) Reasons
for Nonadherence to Medications (ACTGrev) is a self-report
measure of reasons for missing medications that was revised
through a randomized clinical trial on adherence.26,27 The revised scale consists of two factors with a total of nine items (pilltaking problems [5 items] and forgetfulness [4 items]) using a
four point Likert-type scale ranging from 0 = never to 3 = often.
A higher score indicates less adherence to medication regimens. Cronbach’s a for the two subscales and the total scale
ranged from 0.8 to 0.9.
6. The Revised Sign and Symptom Checklist for
HIV (SSC-HIV). This 72 item checklist asks respondents to

Data analysis
The analysis for this study used parametric and nonparametric repeated-measures tests for GSE and the perceived
effectiveness by the participant of SCSMS for the selected
symptoms of anxiety, depression, diarrhea, fatigue, nausea,
and neuropathy. We grouped the self-care strategies for all six
previously mentioned symptoms into categories of strategies
for each symptom. Symptom burden was assessed by examining symptom frequencies with the SSC-HIV-rev. Demographic variables were also examined. Engagement with the
provider and the health and medication worry dimensions
from the HAT-QoL were analyzed with regard to self-efficacy.
The GSE scale was split above and below the median (median = 30) to create high (HSE) and low (LSE) self-efficacy
groups. For both self efficacy groups, the symptom intensity
mixed model growth estimations were computed by testing
the unconditional means model to each individual’s initial
symptom intensity status at baseline (within person) and its
associated variation from the mean symptom intensity value.
Results
The mean age for the sample participants (n = 569) who
completed the self-efficacy scale was 42.8 years (SD = 9.6) and
the gender composition was 38% (n = 218) female, 59.7%
(n = 340) male, and 2% (n = 11) transgender. The participants
were 39.9.1% (n = 227) African/African American, 17.9%
(n = 102) Caucasian, 34.3% (n = 195) Hispanic, 1.8% (n = 10)
Asian/ Pacifica Islander, and 5.3% (n = 30) self-described as
‘‘Other.’’ Most participants, 39% (n = 222) had a high school
education, 30.4% (n = 173) had a grade school education, and
30.6 % (n = 174) had college or post-high school education. Of
this sample, 24.5% (n = 139) worked for pay. The HIV illness
characteristics indicate that the mean number of years living
with HIV were 14.8 years (SD = 6.4), and that 42% (n = 240)
had an AIDS diagnosis, 66.8% (n = 370) reported a comorbid
illness, and 72.9% (n = 412) were presently taking ARV medications (data not shown).
To explore the impact of GSE on self-care symptom management, participants were divided into high and low GSE
groups with 44.8% (n = 252) in the high GSE group and
55.2% (n = 317) of the participants in the low GSE group.
An examination of the differences by GSE category of the
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sociodemographic characteristics of the sample indicates that
the sample is significantly different by gender ( p = 0.02), ethnicity ( p = 0.03), education ( p = 0.007), whether respondents
work for pay ( p = 0.038), and whether they know their viral
load ( p = 0.006). There are no significant differences by age,
years that individuals were HIV positive, whether they are
taking ARV medications presently, or the numbers of years
taking antiretroviral ARV medications (see Table 1).
Strategies for self-care symptom management for the six
symptoms (anxiety, depression, diarrhea, fatigue, nausea,
neuropathy) differed depending upon the symptom although
there were a number of commonalities. The categories of activities/thoughts, medications, and substance use were general strategies used for all of the symptoms. Other self-care
strategies, those for diarrhea for example, also included
foods to eat; and for another symptom the category foods to
avoid, a category that was specific to that symptom, was
included. Table 2 depicts the data for activities/thoughts, the
only general strategy category that was significant for all
symptoms.
A comparison of these SCSMS by GSE group indicates that
there were significant differences in the use of prescribed or
over-the-counter medications and substance use. When the
effectiveness of these strategies was considered, only substance
use was significantly different ( p = 0.04) in the two GSE groups.
Substance use was higher in the low GSE group as was the use
of the other strategies in the low GSE group. The high GSE

group was more likely to be engaged with their HCP ( p = 0.001
and adherent to their medications ( p = 0.001) (see Table 3).
Analysis of change over time
When symptom burden, measured by symptom frequency
is considered, the high GSE group had a lower symptom
frequency at baseline and maintained an advantage in the
additional two assessments, although the symptom frequency
declined for both groups over time. These differences are
significant at the ( p = 0.015) level (see Fig. 2).
For both GSE groups, the symptom intensity mixed model
growth estimations were computed by testing the unconditional means model to each individual’s initial symptom intensity status at baseline (within person) and its associated
variation from the mean symptom intensity value (see Table
4, Model A). The model has no growth parameter. In the
initial model (Model A), there was a significant decrease in
symptoms in this subsample over the 3 month period. This
model showed the symptom intensity intercept value to be
0.92 antilog (-0.079) with significant variation in an individual’s initial status of symptom intensity scores at baseline
(0.005) and in within-person change (0.003). This was calculated to be 0.63 (0.005/0.005 + 0.003), indicating that almost
two-thirds of the total variation in symptom intensity was
attributable to differences among the participants. This value
also indicated that there was large residual autocorrelation as
expected in repeated measures analyses.

Table 1. Demographic Characteristics (n = 569) of Those Completing the General Self-Efficacy Instrument
High self efficacy
group (HSE) n = 253
Gender
Male
Female
Transgender
Age mean (SD)
Ethnicity
Black
Non-black
Hispanic
White
Other (Asian, Native American, others)
Highest education level
Grade school
High school
College (Associate)
College (Bachelors)
Masters/higher
Work for pay
Yes
No
Years HIV + mean (SD)
Taking ARVs now
Yes
No
Years taking ARVs mean (SD)
Does not know HIV VL
Knows VL undetectable
Knows detectable VL value
ARV, antiretroviral medication; VL, viral load.

176
84
5
44.0

(52%)
(38%)
(2%)
(9.8)

Low self efficacy
group (LSE) n = 316
164
134
6
42.7

(48%)
(62%)
(2%)
(8.8)

89 (35%)

138 (44%)

97 (38%)
54 (17%)
24 (8%)

98(31%)
48 (19%)
21 (8%)

66
92
57
26
13

(26%)
(36%)
(22%)
(10%)
(9%)

107
130
54
18
6

p
Value

Male to female
only
v2 (1,558) = 5.07

0.02

t (548) = 1.61
Black/Non-black
only
v2 (1,569) = 4.80

0.10
0.03

v2 (4,569) = 13.9

0.007

v2 (1,568) = 14.32

0.038

t (548) = 1.22
v2 (1,565) = 2.1

0.22
0.15

t (212) = 0.598
v (2,559) = 10.1

0.55
0.006

(34%)
(41%)
(17%)
(6%)
(2%)

73 (28%)
182 (71%)
10.1 (6.4)

66 (21%)
247 (79%)
9.5 (6.4)

192
61
7.1
89
109
51

220
92
6.7
129
96
85

(76%)
(24%)
(5.1)
(36%)
(44%)
(20%)

v2, or t

(70%)
(30%)
(5.1)
(42%)
(31%)
(27%)

2

Table 2. Specific Activities and Thoughts Mentioned for Each Symptom
Activities/thoughts
Talk with family/friends
Talk with HCP
Talk with others with HIV
Attend support groups
Denial/Try not to think
Cry
Stay alone
Talk myself through it
Watch TV
Play cards
Read
Cook
Avoid negative or annoying thing
Go out to work
Treat myself with special foods
Keep busy
Draw
Listen to music
Don’t dwell on it
Get enough sleep at night
Take frequent breaks
Adjust social activities
Not get stressed out
Nap during the day
Lie down and rest
Take a deep breath
Rub the stomach
Get fresh air
Take a hot bath or shower
Stay off your feet

Anxiety

Depression

Diarrhea

X
X
X
X
X
X
X
X
X
X
X
X

X
X
X
X
X

X

Fatigue

Nausea

Neuropathy

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

X
X

HCP, healthcare provider.

Table 3. Self-Care Symptom Management Strategy by Self-Efficacy
Bivariate analyses–self care symptom management strategy type used
Self care symptom management category n = 569

High self efficacy
group (HSE)

Low self efficacy
group (LSE)

Value

p

Thoughts and activities frequency – (mean rank)

272.86

299.37

ZU = 1.91

Taking prescribed and OTC medications therapies
frequency – (mean rank)
Exercise frequency – (mean rank)
Complementary therapies frequency – (mean rank)
Substance use frequency–(mean rank)
Thoughts and activities effectiveness – (mean rank)
Taking prescribed and OTC medications therapies
effectiveness – (mean rank)
Exercise effectiveness–(mean rank)
Complementary therapies effectiveness–
(mean rank)
Substance use effectiveness-(mean rank)
HIV assessment tool (HAT)

271.92

300.13

ZU = 2.17

p = 0.056
(CI = 0.050–0.062)
p = 0.030

281.10
282.46
271.78
276.01
278.37

292.69
291.59
300.25
296.82
294.91

ZU = 0.870
ZU = 0.687
ZU = 0.025
ZU = 1.51
ZU = 1.25

p = 0.38
p = 0.49
p = 0.025
p = 0.13
p = 0.21

285.92
286.66

288.78
288.06

ZU = 0.22
ZU = 0.20

p = 0.83
p = 0.82

273.67

298.71

ZU = 1.98

p = 0.04

t = 4.20

p £ 0.001

HIV control over illness (taking/not taking ART)
75.34 (SD = 26.0)
Engagement with health care provider (HCP)
HCP total score (lower score = improved
14
engagement)
Symptom frequency (SSC-HIV rev) total score (range 0–64)

56.70 (SD = 29.9)

19.40 (SD = 17.9)
17.37 (SD = 15.8)
14.02 (SD = 13.9)

23.0 (SD = 19.5)
20.62 (SD = 19.8)
17.97 (SD = 18.5)

Baseline
Assessment 1
Assessment 2

ZU, Mann–Whitney nonparametric statistical test; ART, antiretroviral therapy.
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t=

F = 5.90

p £ 0.001

p = 0.015
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Table 4. Multilevel Analysis of Change Over Time–Dependent Variable (DV) = Log of Total Symptom
Unconditional
growth model

Growth model
with GSE 2 groups

Model A

Model B

Growth model with all level 2
predictors and covariates
Model C
SE

Model C

1.206a

0.039

- 0.067a

0.012

Black

0.095b

0.042

Female

0.021

0.042

0.087b

0.042

Activities_eff

0.008b

0.004

Activities_used

0.008

0.004

[gse2grp = 1.00]a
activities_useda
black

- 0.010b

0.004

[gse2grp = 1.00]a
timea
activities_useda
black

0.001

0.003

[gse2grp = 0.00]a
activities_used

0.010

0.006

- 0.008

0.006

There is significant variation about
the intercept in symptom intensity
There is a significant decrease in
symptom intensity in both groups
over the 3-month period
Black individuals had a significantly
higher symptom intensity rating
at baseline compared with other
ethnicities
Females had a significantly higher
symptom intensity rating at
baseline compared with male and
transgender individuals
Individuals in the low self efficacy
group had a significantly higher
symptom intensity at baseline
compared with the high GSE group
Individuals who rated activities
effectiveness higher had increased
symptom intensity scores at baseline
Individuals who used more symptom
management activities had increased
symptom intensity scores at baseline
Black individuals in the high self
efficacy group used significantly
fewer activities compared with
non-black individuals at baseline
Black individuals in the high selfefficacy group remained constant over
3 months in using fewer activities
compared with non-black individuals,
but not significantly fewer activities
The low self efficacy group did not
use more strategies at baseline
compared with the high self
efficacy group
The low self efficacy group did not
rate strategy effectiveness differently
at baseline compared with the high
self efficacy group

Intercept
Time

Estimate

SE

Estimate

SE

- 0.079

0.009

- 0.090a

0.011

1.377

0.020

1.399a

0.027

0.137a

[gse2grp = 0.00]

0.034

[gse2grp = 0.00]a
activities_eff
Model fit statistics
- 2 log likelihood

Estimate

Interpretation

1996.0

1409.9

1219.2

Akaike information
criterion (AIC)
Schwarz’s Bayesian
criterion (BIC)
Residuals analysis
Residual in model
Residual variance intercept

1986.0

1397.9

1255.2

2023.2

1441.0

1347.8

0.003
0.005

0.013
0.0009

0.090
0.132

0.005
0.012

0.088
0.104

0.005
0.010

Residual variance time

0.195

0.087

0.004

0.003

0.002

0.003

a

p £ 0.001, bp £ 0.05.

The model fit improved with the
addition of explanatory level 2
variables

21% of the variance has been
explained from model B with the
addition of the additional level
2 variables
50% of the variance in time is
explained by the addition of
level 2 variables

EXPLORING CONTRIBUTION OF SELF-EFFICACY

FIG. 2. Symptom intensity by self-efficacy.
Next, the addition of the GSE group variable to obtain the
individual growth trajectories from baseline as well as the
between-person variation in trajectories was estimated. In this
model, the intercept symptom intensity value was 0.81 antilog
(0.09) and again, over time on average, whereas both groups
decreased in the symptom intensity scores, the low GSE group
had a significantly higher increase in the intercept for symptom intensity 1.11 antilog (-0.09 + 0.137) that continued over
the 3-month period. The variances showed significant individual variation about the individual trajectories (0.09) as well
as significant between-person variability in initial status
(0.132) and the rate of change (0.004). The addition of the selfefficacy group variable increased the variation about the initial intercept and explained little of the variation. However,
the smaller goodness of fit statistics relative to Model A
showed that the model was a better fit. The estimates of
variation from these two unconditional models were used for
the subsequent model comparison to assess any further reduction in variance, and improved model fit by the addition
of level 2 variables (self-efficacy and other descriptive variables) in describing the sample and to reduce variation. Model
C shows the final model that tested the effects of adding additional independent variables for the use of self-management
activities and demographic data, and the modeled interactions of these variables, to assess the effects of symptom intensity change over time. Whereas 21% of the variance in
Model B was explained by the addition of level 2 variables,
50% of the variance in GSE over time was explained in Model
C (see Table 4). Black individuals had a significantly higher
intensity rating at baseline compared with other ethnicities
and those with high GSE scores, and used significantly fewer
activities for self-care management than those used by nonblack individuals at baseline.
Discussion
As was noted in the results, demographic characteristics
make a difference with regard to general self-efficacy as evidenced by our finding that females, blacks, those who do not
work, individuals with a high school education or less, and
those who don’t know their viral load were all more likely to
be in the low GSE group. Demographic characteristics were
also significant with regard to symptom intensity, with both
blacks and females having higher symptom intensity at
baseline. This raises the question about whether GSE has an
impact on access to care or the attention of the HCP, or
whether lack of such access and attention result in lower GSE.
It is plausible that there is a recursive effect, with self-efficacy
affecting the interaction with the HCP and the interaction
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with the HCP affecting self-efficacy. Our results indicate a
significant ( p = < 0.001) difference in engagement with the
HCP by GSE with those who had lower GSE experiencing less
engagement with their providers. Engagement with the provider has been found to be important both to ARV adherence
and retention in care.32,33 Self-efficacy may provide yet another indicator as to those who will require greater attention
by providers.
GSE also made a difference with regard to symptom burden. The high GSE group had lower symptom intensity than
did the low GSE group at baseline, and over the three time
periods. Again, engagement with the provider may be part of
the explanation for this finding. Nonetheless, there is a decline
in symptom frequency over the three time periods for both the
high and low GSE groups. Whether this is a result of the
attention obtained by participation in the study could not be
determined with the data at hand.
Symptom intensity did have an impact on the use of
SCSMS. Individuals who used more strategies had increased
symptom intensity at baseline, suggesting that intensity led
these individuals to experiment with a number of approaches
to reduce their discomfort. Further, individuals who rated the
effectiveness of these strategies higher also had increased
symptom intensity at baseline. It should be noted that individuals in the low GSE group had higher symptom intensity
at baseline compared with the high GSE group.
Our data indicated that the high and low GSE groups differed with regard to the number and type of SCSMS utilized.
However, black individuals in the high GSE group used significantly fewer activities compared with non-blacks, suggesting that race may be less important than other factors for
individuals with high GSE. Whether this indicates the ability
to be more selective and efficacious in determining which
strategies to use requires further study.
Another difference between high and low GSE groups in
the type of strategies used included the categories of taking
prescribed and over-the-counter medications and substance
use. The effectiveness of substance use was the only category
of strategies that differed between the two GSE groups. This
raises questions about the perceived inadequacy of the treatment of symptoms. Given that substance use has been found
to have a negative relationship with adherence, more attention to the treatment of symptoms is required. Our data indicated a significant ( p = < 0.001) difference between the high
and low GSE groups regarding adherence to ARV medications, underscoring the importance of addressing substance
use and ARV therapy in low GSE individuals. GSE was considered a modifiable factor by Arnsten and colleagues.34 This
suggests that interventions to enhance GSE may be developed. Further, given our findings that the high GSE group had
significantly better engagement with the provider than did
the low GSE group, the importance of the provider cannot be
overemphasized. The provider is only part of the equation,
however, and attention to the empowerment of the patient, a
far more complex issue, requires further attention as well.35
Our data indicate that there are differences in the perceived
symptom burden over time of HIV-infected individuals by
perceived GSE. Those individuals with higher GSE had fewer
symptoms, and these symptoms were perceived to be less
intense than those experienced by the low GSE group.
Perceived GSE was related to the type, frequency, and effectiveness of the SCSMS used by HIV-infected individuals. And
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whereas there were no differences in the high and low GSE
groups in the frequency of use of the thoughts/activities, exercise, and complementary therapies, there were significant
differences in the use of prescribed and over-the-counter medications and substance use. However, only substance use was
significantly different in effectiveness in the two GSE groups.
Ultimately, the gold standard in the self-care management of
symptoms is the effectiveness of the strategies selected. Given the
difference in substance use by perceived GSE and the importance
of engagement with the HCP, more attention to the resolution of
the concerns of those with low GSE by HCP is warranted.
Our results showed that individuals in the low GSE group
were more likely to use substances as a SCSMS. Our data did
not indicate, however, whether these individuals as compared with those in the high GSE group were more likely to
use substances recreationally. Such a distinction would be
helpful for making recommendations. Our data cannot inform us as to whether recreational use led to the serendipitous
finding of symptom relief.
This study would have benefited by having included instruments measuring performance self-efficacy so as to ascertain the degree of association with GSE. Such instruments
might include adherence self-efficacy and condom self-efficacy.
GSE was divided into high and low groups using the median.
Other approaches to determining group membership, including using a high, medium, and low group categorization, may
enhance our understanding of GSE, particularly when combined with performance-related measures.
This study has demonstrated the significance of GSE in
identifying individuals who are more likely to use substance
use as a SCSMS. And although Bandura and others indicate
that GSE must be specified with regard to a particular activity
such as adherence self-efficacy, it may be that those with high
GSE are more likely to have higher adherence self-efficacy. It
is plausible that for those activities that don’t require special
skills or training, GSE may provide the foundation of confidence necessary to incorporate the behaviors required to
achieve adherence. Further research to investigate the relationship of GSE with a range of specified self-efficacy behaviors will enhance our understanding of the role of selfefficacy in healthcare outcomes. Additional study on the use
of substances for symptom management is also warranted.
Would such use occur if symptoms were managed more effectively? Although the common-sense response might be in
the affirmative, further research would refine our understanding of this question.
The finding that individuals in the low GSE group were
more likely to utilize substances as a SCSMS indicates that
symptoms are not being adequately addressed by HCP.
Whether this is because individuals with low GSE do not
present their concerns and complaints, or that these individuals are not queried about their concerns, the result is that
they do not receive the care required. It is possible that those
with low GSE have a greater range of issues that need to be
addressed than those with higher GSE, and that therefore only
the most significant, as perceived by the HCP, are treated in
the limited time available. The constraints of time may ultimately prove to be penny wise and pound foolish.
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